(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada...
Stats | |
---|---|
本日の出来高 | 72.25M |
平均出来高 | 7.97M |
時価総額 | 0.00 |
EPS | $-0.140 ( 2021-08-16 ) |
Last Dividend | $47.50 ( 1995-12-13 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0403 |
ATR14 | $0.0270 (15.56%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-07-21 | Ben-maimon Carole | Buy | 150 000 | Restricted Stock Units |
2021-07-21 | Celentano John E | Buy | 150 000 | Restricted Stock Units |
2021-07-21 | Marth William S | Buy | 150 000 | Restricted Stock Units |
2021-07-21 | Pate R Carter | Buy | 150 000 | Restricted Stock Units |
2021-07-16 | Yachmetz Philip K | Buy | 7 835 | Restricted Stock Units |
INSIDER POWER |
---|
0.00 |
Last 94 transactions |
Buy: 6 929 847 | Sell: 975 703 |
ボリューム 相関
Teligent Inc (NEW JERSEY) 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Teligent Inc (NEW JERSEY) 相関 - 通貨/商品
Teligent Inc (NEW JERSEY) 財務諸表
Annual | 2020 |
収益: | $45.31M |
総利益: | $45.31M (100.00 %) |
EPS: | $0 |
FY | 2020 |
収益: | $45.31M |
総利益: | $45.31M (100.00 %) |
EPS: | $0 |
FY | 2019 |
収益: | $65.90M |
総利益: | $23.52M (35.70 %) |
EPS: | $-4.70 |
FY | 2017 |
収益: | $67.25M |
総利益: | $27.37M (40.70 %) |
EPS: | $-2.80 |
Financial Reports:
No articles found.
Teligent Inc (NEW JERSEY) Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $47.50 | 1995-12-13 |
Last Dividend | $47.50 | 1995-12-13 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $47.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0 | 1.500 | -1.111 | -1.667 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.916 | 0.800 | 5.42 | 4.34 | [1 - 3] |
quickRatioTTM | 0.744 | 0.800 | -0.329 | -0.263 | [0.8 - 2.5] |
cashRatioTTM | 0.257 | 1.500 | 9.68 | 10.00 | [0.2 - 2] |
debtRatioTTM | 1.636 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.217 | 2.00 | -0.0725 | -0.145 | [0 - 30] |
freeCashFlowPerShareTTM | -0.270 | 2.00 | -0.135 | -0.270 | [0 - 20] |
debtEquityRatioTTM | -1.246 | -1.500 | -4.98 | 7.47 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.988 | 1.000 | 10.00 | 10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.122 | 1.000 | -1.790 | -1.790 | [0.2 - 2] |
assetTurnoverTTM | 0.540 | 0.800 | 9.73 | 7.79 | [0.5 - 2] |
Total Score | 3.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0 | 1.000 | -0.101 | 0 | [1 - 100] |
returnOnEquityTTM | 0 | 2.50 | -0.714 | -1.667 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.270 | 2.00 | -0.0899 | -0.270 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.217 | 2.00 | -0.0725 | -0.145 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.370 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.721 |
Teligent Inc (NEW JERSEY)
Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。